Joshua Zeidner/ X ; Daniel Peters/ X
Jul 13, 2026, 10:49
Joshua Zeidner: Advancing Menin Inhibitor Therapy in MD Education AML-ALL US Focus 2026
Joshua Zeidner, Professor of Medicine at The University of North Carolina at Chapel Hill, shared Daniel Peters‘s post on X, adding:
“True privilege to be part of the MD Education AML ALL US Focus 2026 meeting!
Always great to highlight the incredible advances of menin inhibitors and excited to discuss our upcoming RAVEN.
Study for newly diagnosed younger/fit KMT2Ar AML.”
Daniel Peters, Assistant Professor at Medical College of Georgia at Augusta University and Member of the Georgia Cancer Center, shared a post on X:
“One of the many great talks at MD Education AML-ALL focus group.
Joshua Zeidner at UNC Lineberger showing continued, impressive results of Menin-I in NPM1 and KMT2Ar AML and emphasis on frontline combos.
Tip of the iceberg!”
-
Aug 11, 2026, 11:47Rucha Patil: Strengthening Evidence-Based Haemophilia Care Across India
-
Aug 11, 2026, 11:38Maria Hadjidemetriou: The Patient Perspective in Thalassemia Care
-
Aug 11, 2026, 11:04Wolfgang Miesbach: The Critical Need for Tailored Dosing in VWD
-
Aug 11, 2026, 08:20Hasan Abbas Zaheer: Strengthening Universal Access to Safe Blood in Pakistan
-
Aug 11, 2026, 08:07Nicola Pozzi: Advancing Hemostasis Through Scientific Collaboration at Hemostasis GRC
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:41Kevin Land: How Cellular Therapy Is Changing Transfusion Medicine
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy